E-mail not displaying correctly? View it in your browser.
Upgrade Your Cell-Based Assays to 3D
Our Products
& Services

Click to find
more about our

In this newsletter

InSphero wins grant to develop new 3D microtissues
After a competitive selection process, InSphero received a 1.25 mio US$ grant from the Swiss Commission of Technology and Innovation to develop new 3D microtissues, including cardiomyocyte, neuronal and kidney products. See here, what we are going to do.
3D cell culture literature picks – Mar 2012
Again, our applications team has reviewed a small selection of current 3D-cell-culture journal papers this month to keep you up-to-date about recent developments in 3D.

Titles of papers reviewed:
3D Cell Culture 2012 sets record with 240 participants
In March, 240 scientists from industry and academia met in Zurich at the international 3D Cell Culture 2012 meeting to discuss technology, applications and implementation of 3D cell culture for compound testing. Learn more about the conference here.

Next InSphero customer workshop on June 11 in Zurich
InSphero's 2012 European Customer Workshop will offer the following:
  • A basic introduction to 3D microtissues and applications
  • NEW: For experienced microtissue users - hands-on labs and lectures on advanced topics including histology and 3D biochemical assays (session runs parallel to the introductory 3D cell culture talks).
  • NEW: Presentations from industrial and academic users of 3D microtissues about results and applications.
This full-day event will be held in Zurich, Switzerland on June 11, 2012, starting at 8:30am. Request more information here.

InSphero workshop in Copenhagen, Denmark, Feb 2012

Meet InSphero at AACR 2012 next week & other fairs
Meet the InSphero team at AACR 2012 in Chicago next week and at other upcoming fairs, conferences and workshops to learn how scaffold-free organotypic 3D microtissues, and 3D optimized assays, accelerate the process of drug discovery and development.

To arrange a meeting or a webinar, or register for a workshop please send us an E-mail.

About InSphero

InSphero is a leading supplier of organotypic, biological in-vitro 3D microtissues for highly predictive drug testing. The company, headquartered in Zurich, Switzerland, currently counts 6 of the top ten global pharmaceutical and cosmetics companies as customers, and is helping them implement the company’s patent-pending microtissue technology in their development work-flow. InSphero’s 3D microtissues are scaffold free, highly reproducible and delivered in an automation-compatible 96-well format to replace conventional 2D cell assays for better biological relevance and predictivity. The 3D cancer microtissues reflect tumor physiology and are used routinely for screening. For toxicology and metabolics applications, rat and human 3D liver microtissues predict even rare cases of idiosyncratic toxicology and remain viable for more than 5 weeks for chronic studies. InSphero’s off-the-shelf portfolio of assay-ready microtissues is complemented by custom-made 3D microtissues with a development time of 4-6 weeks and production turnaround of less than 10 days.
InSphero is a spin-off company of the Swiss Federal Institute of Technology (ETH) Zurich and the University Zurich. The company was recognized for its scientific and commercial achievements with a number of awards, including the VentureKick award, Heuberger Entrepreneurial Award, CTIstartup certification and the SLAS New Product Award (NPA) 2011 Designation. InSphero is also officially certified to the ISO 9001:2008 standard for its Quality Management System.

Our mailing address is:
InSphero Inc.
74 Orion St
Brunswick, ME 04011-5031

Copyright (C) 2012 InSphero Inc. All rights reserved.